Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 5, 2007

Cenomed Coawarded Chemical Defense Grant

  • Cenomed BioSciences along with coinvestigators at Wright-Patterson Air Force Base and Wright State University received a three-year grant to evaluate certain molecules as drug combinations following nerve agent exposure. The other recipients are Major David Watson of the Air Force Research Laboratory and James Lucot, Ph.D., associate professor of pharmacology and toxicology.

    The funding from the Defense Joint Science and Technology Office for Chemical and Biological Defense/Threat Reduction Agency will go toward preclinical studies of selected defense compounds from Cenomed’s library. The collaborators say that they will emphasize combinations that enhance currently approved treatments.

    Cenomed plans to synthesize compounds and conduct preclinical safety studies. The Air Force Research Laboratory and Wright State University will further evaluate the effectiveness of these candidates following chemical warfare agent exposure.

    Cenomed reports that its compounds are being developed as a pre- and postexposure therapy for military and civilian victims of a chemical nerve agent attack.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »